This is a multicenter, randomized, double-blind, parallel, placebo-controlled, multiple dose study that will enroll approximately 40 systemic lupus erythematosus subjects with active lupus arthritis.

Inclusion Criteria:

• Diagnosis of SLE for at least 6 months as defined by the most recent American College of Rheumatology criteria
• Presence of lupus related inflammatory arthritis with at least four tender and four swollen joints; and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) ≥ 6 at screening;
• Other inclusion criteria may apply.

Exclusion Criteria:

• Presence or history of vasculitis, and presence or history of active lupus nephritis requiring therapy within the last 3 years
• Any disorder (including psychiatric), condition, clinically significant disease, disease activity related to SLE
• Positive for HIV antibodies, hepatitis B surface antigen or anti-HBc, or hepatitis C antibodies
• Known residential exposure to an individual with tuberculosis or positive Quantiferon test or PPD test at screening
• Men and women of reproductive potential, unwilling to practice a highly effective method of birth control for the duration of the study
• Other exclusion criteria may apply